CellGENTherapies produces advanced gene-, cell- and tissue-therapeutic products (ATMPs) for early phase clinical trials according to good manufacturing principles (GMP). We focus on the development and production of small batches of ATMPs (including personalized products) and prophylactic RNA vaccines for phase I studies, helping Gent University Hospital, external clients and partners to move their research “from bench to bedside”.

CellGENTherapies was founded in 2014. In 2016 the first ATMP was produced under GMP conditions. Ever since, the activity has been growing. CellGENTherapies is currently licensed for the production of investigational advanced therapy medicinal products and we are currently applying for a license for the production of microbial vaccines.

CellGENTherapies, located on the campus of Ghent University Hospital, ensures synergies with both the hospital and Ghent University. It also benefits from Ghent’s reputation as leading cluster for biotech and medical companies, and its position as gateway to Europe and the world.